Search results for "DEXA"

showing 10 items of 264 documents

Topical Application of Glycolipids from Isochrysis galbana Prevents Epidermal Hyperplasia in Mice

2017

Chronic inflammatory skin diseases such as psoriasis have a significant impact on society. Currently, the major topical treatments have many side effects, making their continued use in patients difficult. Microalgae have emerged as a source of bio-active molecules such as glycolipids with potent anti-inflammatory properties. We aimed to investigate the effects of a glycolipid (MGMG-A) and a glycolipid fraction (MGDG) obtained from the microalga Isochrysis galbana on a TPA-induced epidermal hyperplasia murine model. In a first set of experiments, we examined the preventive effects of MGMG-A and MGDG dissolved in acetone on TPA-induced hyperplasia model in mice. In a second step, we performed…

Keratinocytes0301 basic medicineglycolipidsAdministration Topicalmedicine.medical_treatmentPharmaceutical SciencePharmacologyIsochrysis galbanaOintmentsMGDGMiceDrug DiscoveryMicroalgaelcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)Skinintegumentary systembiologyChemistrymicroalgaeHaptophytaHyperplasiaepidermal hyperplasiaCytokineIsochrysis galbanaCytokinesTetradecanoylphorbol AcetateFemalemedicine.drugskinglycolipids; <b>MGDG</b>; skin; inflammation; epidermal hyperplasia; microalgae; <i>Isochrysis galbana</i>Cell SurvivalDrug CompoundingSkin AbsorptionSkin DiseasesArticle03 medical and health sciencesGlycolipidIn vivoPsoriasismedicineAnimalsHumansDexamethasoneInflammationHyperplasiamedicine.diseasebiology.organism_classificationEpidermal hyperplasia030104 developmental biologylcsh:Biology (General)inflammationGlycolipidsEx vivoMarine Drugs
researchProduct

Thyroid cartilage involvement in patient affected by IgA multiple myeloma: case report.

2008

Neoplasms originating from plasma cell are rare in the head and neck region. A correct clinical evaluation is very important in order to formulate a differential diagnosis as well as to distinguish local from metastatic disease. We report a case of larynx involvement by an IgA multiple myeloma in a 69-year-old female diagnosed in October 2004 and treated with chemotherapy; the 1 year control do not show progression of disease and the laryngeal lesion is unchanged. We highlight the radiological findings and clinical features to suspect plasma cell tumors in cases with a similar presentation.

LarynxPathologymedicine.medical_specialtyThyroid cartilagemedicine.medical_treatmentDiseasePlasma cellDexamethasoneMultiple myelomaAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLaryngeal NeoplasmsMultiple myelomaMultiple myeloma; Thyroid cartilage; Plasma cell tumor of larynxAgedChemotherapybusiness.industryGeneral Medicinemedicine.diseaseThyroid cartilageImmunoglobulin Amedicine.anatomical_structureOtorhinolaryngologyDoxorubicinVincristineFemaleSurgeryPlasma cell tumor of larynxDifferential diagnosisPresentation (obstetrics)Tomography X-Ray Computedbusiness
researchProduct

Linfomi e salute dell'osso : è possibile migliorare la qualità di vita?

Linfoma osteoporosi DEXA denosumab bisfosfonati
researchProduct

Modulation of Nitric Oxide Production by Tetracyclines and Chemically Modified Tetracyclines

1999

Chemically modified tetracyclines (CMTs) dose-dependently decreased inducible nitric oxide synthase (iNOS) and, consequently, nitric oxide (NO) formation by the lipopolysaccharide (LPS)-stimulated J774 line. The inhibitory effect was due to a specific reduction in the iNOS protein content in the cells, as attested by Western blot analysis and by the inhibition of iNOS mRNA accumulation. Furthermore, CMTs cause a dose-dependent increase in cell death in the J774 line mediated by the NO-independent apoptotic mechanism.

Lipopolysaccharides0301 basic medicineLipopolysaccharideApoptosisNitric OxideDexamethasoneCell LineNitric oxideMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineWestern blotmedicineAnimalsInos proteinInhibitory effectomega-N-MethylarginineDose-Response Relationship Drugmedicine.diagnostic_testbiologyMacrophages030206 dentistryGeneral MedicineNitric oxide synthase030104 developmental biologychemistryBiochemistryTetracyclinesApoptosisInos mrnabiology.proteinNitric Oxide SynthaseAdvances in Dental Research
researchProduct

The macrophage-activating tetrapeptide tuftsin induces nitric oxide synthesis and stimulates murine macrophages to kill Leishmania parasites in vitro.

1994

The macrophage-activating tetrapeptide tuftsin was able to activate, in a dose-dependent manner, murine macrophages to express nitric oxide (NO) synthase and to produce NO. Tuftsin required lipopolysaccharides for the optimal induction of NO production and synergized with gamma interferon in the induction of NO synthesis. Tuftsin-dependent NO production was sensitive to inhibition by dexamethasone and the NO synthase specific inhibitor LGN-monomethylarginine (L-NMMA). Murine peritoneal macrophages activated by tuftsin were able to kill the amastigotes of the intracellular protozoan parasite Leishmania major in vitro.

LipopolysaccharidesImmunologyTuftsinArginineNitric OxideMicrobiologyDexamethasoneNitric oxidechemistry.chemical_compoundInterferon-gammaMicemedicineMacrophageAnimalsLeishmania majorInterferon gammaLeishmania majorMice Inbred BALB Comega-N-MethylargininebiologyMacrophagesMacrophage Activationbiology.organism_classificationLeishmaniaCell biologyNitric oxide synthaseInfectious DiseaseschemistryBiochemistrybiology.proteinOmega-N-MethylarginineTuftsinParasitologyFemalemedicine.drugResearch ArticleInfection and immunity
researchProduct

Budlein A from Viguiera robusta inhibits leukocyte-endothelial cell interactions, adhesion molecule expression and inflammatory mediators release

2009

Budlein A has been reported to exert some analgesic and anti-inflammatory properties. In this study, we have evaluated its effect on LPS-induced leukocyte recruitment in vivo and the mechanisms involved in its anti-inflammatory activity. In vivo, intravital videomicroscopy was used to determine the effects of budlein A on LPS-induced leukocyte-endothelial cell interactions in the murine cremasteric microcirculation. In vitro, the effects of budlein A on LPS-induced cytokine, chemokine and nitrites release, T-cell proliferative response as well as cell adhesion molecule expression (CAM) were evaluated. In vivo, intraperitoneal administration of budlein A (2.6 mM/kg) caused a significant redu…

LipopolysaccharidesMaleChemokineT-Lymphocytesmedicine.medical_treatmentPharmaceutical ScienceLeukocyte RollingCell CommunicationAsteraceaeNitric OxideDexamethasoneCell LineLactonesMiceIn vivoDrug DiscoverymedicineAnimalsHumansLeukocyte RollingInterleukin 8NitritesCell ProliferationPharmacologyMice Inbred BALB CbiologyPlant ExtractsCell adhesion moleculeMacrophagesMicrocirculationMonocyteEndothelial CellsCell biologyMice Inbred C57BLEndothelial stem cellmedicine.anatomical_structureCytokineComplementary and alternative medicinebiology.proteinMolecular MedicineChemokinesCell Adhesion MoleculesSesquiterpenesImmunosuppressive AgentsPhytomedicine
researchProduct

Nitric oxide synthase activity is inducible in rat, but not rabbit alveolar macrophages, with a concomitant reduction in arginase activity

1995

Alveolar macrophages were obtained by broncho-alveolar lavage of isolated rat and rabbit lungs and cultured (2.5 × 106 cells/dish) for 18 h in the absence or presence of bacterial lipopolysaccharides (LPS) alone or in combination with cytokines. Thereafter, accumulation of 3H-citrulline (NO synthase activity) and 3H-ornithine (arginase activity) were determined. During incubation of rat alveolar macrophages with 3H-arginine clear amounts of 3H-citrulline and 3H-ornithine (3.8 and 4.6% of the added 3H-arginine, respectively) were formed and most of these metabolites appeared in the incubation medium (ratios extra-/intracellular of 17 and 70 for 3H-citrulline and 3H-ornithine, respectively). …

LipopolysaccharidesMaleOrnithinemedicine.medical_specialtyArginineIn Vitro TechniquesArginineNitric OxideDexamethasoneNitric oxideRats Sprague-Dawleychemistry.chemical_compoundInternal medicineMacrophages AlveolarmedicineCitrullineAnimalsNitritesPharmacologyomega-N-MethylarginineArginasebiologyGeneral MedicineRatsArginaseNitric oxide synthaseEndocrinologychemistryEnzyme InductionOrnithine transportbiology.proteinCitrullineCytokinesFemaleTumor necrosis factor alphaAmino Acid OxidoreductasesRabbitsNitric Oxide SynthaseIntracellularNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Redox Proteomics of the Inflammatory Secretome Identifies a Common Set of Redoxins and Other Glutathionylated Proteins Released in Inflammation, Infl…

2015

Protein cysteines can form transient disulfides with glutathione (GSH), resulting in the production of glutathionylated proteins, and this process is regarded as a mechanism by which the redox state of the cell can regulate protein function. Most studies on redox regulation of immunity have focused on intracellular proteins. In this study we have used redox proteomics to identify those proteins released in glutathionylated form by macrophages stimulated with lipopolysaccharide (LPS) after pre-loading the cells with biotinylated GSH. Of the several proteins identified in the redox secretome, we have selected a number for validation. Proteomic analysis indicated that LPS stimulated the releas…

LipopolysaccharidesProteomicsglutaredoxins; glutathione; redox signalingBlotting Westernlcsh:MedicineDown-RegulationInflammationBiologyProteomicsmedicine.disease_causeAntioxidantsDexamethasoneCell LineMiceProfilinschemistry.chemical_compoundThioredoxinsInfluenza HumanmedicineExtracellularAnimalsHumansVimentinSulfhydryl Compoundsglutathionelcsh:Scienceredox signalingglutaredoxinsInflammationMultidisciplinarylcsh:RRProteinsPeroxiredoxinsGlutathioneCell biologyBlotOxidative StressRAW 264.7 CellschemistryQR180lcsh:QTumor necrosis factor alphamedicine.symptomPeroxiredoxinOxidation-ReductionOxidative stressResearch ArticlePLOS ONE
researchProduct

Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2

1995

AbstractTo explore the functional role of TIMP-2 in liver, we determined TIMP-2 mRNA levels in primary rat hepatocytes and in total rat liver. Rat hepatocytes constitutively express TIMP-2 mRNA at a low level. Incubation with dexamethasone, prostaglandin E2 and a combination of inflammatory cytokines leads to an up-regulation of TIMP-2 mRNA. In rats in vivo we found a dramatic increase of TIMP-2 expression after intraperitoneal injection of lipopolysaccharide. Compared to our previous findings on TIMP-1 we conclude that TIMP-2 mRNA expression is regulated in a distinct and partially opposite manner. Over-production of TIMP-2 could inhibit the activity of metalloproteinases and thus lead to …

Lipopolysaccharidesmedicine.medical_specialtyLipopolysaccharidemedicine.medical_treatmentInflammatory mediatorIntraperitoneal injectionBiophysicsTissue inhibitor of metalloproteinaseMatrix metalloproteinaseBiochemistryDexamethasoneDinoprostoneCell LineProinflammatory cytokineMicechemistry.chemical_compoundStructural BiologyFibrosisIn vivoInternal medicineGeneticsmedicineAnimalsHumansRNA MessengerProstaglandin E2Molecular BiologyCells CulturedTissue Inhibitor of Metalloproteinase-2ChemistryMetalloendopeptidasesProteinsExtracellular matrixCell BiologyTissue inhibitor of metalloproteinasemedicine.diseaseFibrosisRatsEndocrinologyGene Expression RegulationLiverProtein BiosynthesisCytokinesRat hepatocytemedicine.drug
researchProduct

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

2013

BackgroundWhether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. MethodsIn a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically re…

MESH: Pulmonary EmbolismMale[SDV]Life Sciences [q-bio]Kaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawMESH: Double-Blind Method030212 general & internal medicineMESH: WarfarinMESH: AgedMESH: Middle AgedHazard ratioGeneral MedicineVenous ThromboembolismMiddle AgedThrombosis3. Good healthPulmonary embolismAnesthesiaFemaleAnticoagulants EdoxabanMESH: HemorrhageAndexanet alfamedicine.drugMESH: EnoxaparinHemorrhageMESH: AnticoagulantsMESH: Drug Administration ScheduleDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodAged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; WarfarinmedicineHumansEnoxaparinAdverse effectMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryWarfarinAnticoagulantsmedicine.diseaseMESH: MalechemistryWarfarinbusinessPulmonary EmbolismMESH: FemaleNew England Journal of Medicine
researchProduct